In the phase II TRIUMPH trial (UMIN000027887) which tested the combination of trastuzumab plus pertuzumab in patients with HER2-amplified stage IV CRC, both tissue and ctDNA were used for determining HER2 status. Here, ERBB2 is linked to colorectal carcinoma.